Prognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Non–Small-Cell Lung Cancer Patients

This study aimed to explore the prognostic value of SATB1, SMAD3, and TLR2 expression in non–small-cell lung carcinoma patients with clinical stages I-II. To investigate, we evaluated immunohistochemical staining to each of these markers using tissue sections from 69 patients from our cohort and gen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Justyna Durślewicz MSc, Anna Klimaszewska-Wiśniewska PhD, Jakub Jóźwicki MD, PhD, Paulina Antosik PhD, Marta Smolińska-Świtała PhD, Maciej Gagat PhD, Adam Kowalewski MD, Dariusz Grzanka MD, PhD
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0152040ae90b42beb633b0efa501df80
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0152040ae90b42beb633b0efa501df80
record_format	dspace
spelling	oai:doaj.org-article:0152040ae90b42beb633b0efa501df802021-12-01T23:34:54ZPrognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Non–Small-Cell Lung Cancer Patients1073-274810.1177/10732748211056697https://doaj.org/article/0152040ae90b42beb633b0efa501df802021-11-01T00:00:00Zhttps://doi.org/10.1177/10732748211056697https://doaj.org/toc/1073-2748This study aimed to explore the prognostic value of SATB1, SMAD3, and TLR2 expression in non–small-cell lung carcinoma patients with clinical stages I-II. To investigate, we evaluated immunohistochemical staining to each of these markers using tissue sections from 69 patients from our cohort and gene expression data for The Cancer Genome Atlas (TCGA) cohort. We found that, in our cohort, high expression levels of nuclear SATB1 n and SMAD3 were independent prognostic markers for better overall survival (OS) in NSCLC patients. Interestingly, expression of cytoplasmic SATB1 c exhibited a significant but inverse association with survival rate, and it was an independent predictor of unfavorable prognosis. Likewise, TLR2 was a negative outcome biomarker for NSCLC even when adjusting for covariates. Importantly, stratification of NSCLCs with respect to combined expression of the three biomarkers allowed us to identify subgroups of patients with the greatest difference in duration of survival. Specifically, expression profile of SATB1 n-high /SMAD3 high /TLR2 low was associated with the best OS, and it was superior to each single protein alone in predicting patient prognosis. Furthermore, based on the TCGA dataset, we found that overexpression of SATB1 mRNA was significantly associated with better OS, whereas high mRNA levels of SMAD3 and TLR2 with poor OS. In conclusion, the present study identified a set of proteins that may play a significant role in predicting prognosis of NSCLC patients with clinical stages I-II.Justyna Durślewicz MScAnna Klimaszewska-Wiśniewska PhDJakub Jóźwicki MD, PhDPaulina Antosik PhDMarta Smolińska-Świtała PhDMaciej Gagat PhDAdam Kowalewski MDDariusz Grzanka MD, PhDSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Control, Vol 28 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Justyna Durślewicz MSc Anna Klimaszewska-Wiśniewska PhD Jakub Jóźwicki MD, PhD Paulina Antosik PhD Marta Smolińska-Świtała PhD Maciej Gagat PhD Adam Kowalewski MD Dariusz Grzanka MD, PhD Prognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Non–Small-Cell Lung Cancer Patients
description	This study aimed to explore the prognostic value of SATB1, SMAD3, and TLR2 expression in non–small-cell lung carcinoma patients with clinical stages I-II. To investigate, we evaluated immunohistochemical staining to each of these markers using tissue sections from 69 patients from our cohort and gene expression data for The Cancer Genome Atlas (TCGA) cohort. We found that, in our cohort, high expression levels of nuclear SATB1 n and SMAD3 were independent prognostic markers for better overall survival (OS) in NSCLC patients. Interestingly, expression of cytoplasmic SATB1 c exhibited a significant but inverse association with survival rate, and it was an independent predictor of unfavorable prognosis. Likewise, TLR2 was a negative outcome biomarker for NSCLC even when adjusting for covariates. Importantly, stratification of NSCLCs with respect to combined expression of the three biomarkers allowed us to identify subgroups of patients with the greatest difference in duration of survival. Specifically, expression profile of SATB1 n-high /SMAD3 high /TLR2 low was associated with the best OS, and it was superior to each single protein alone in predicting patient prognosis. Furthermore, based on the TCGA dataset, we found that overexpression of SATB1 mRNA was significantly associated with better OS, whereas high mRNA levels of SMAD3 and TLR2 with poor OS. In conclusion, the present study identified a set of proteins that may play a significant role in predicting prognosis of NSCLC patients with clinical stages I-II.
format	article
author	Justyna Durślewicz MSc Anna Klimaszewska-Wiśniewska PhD Jakub Jóźwicki MD, PhD Paulina Antosik PhD Marta Smolińska-Świtała PhD Maciej Gagat PhD Adam Kowalewski MD Dariusz Grzanka MD, PhD
author_facet	Justyna Durślewicz MSc Anna Klimaszewska-Wiśniewska PhD Jakub Jóźwicki MD, PhD Paulina Antosik PhD Marta Smolińska-Świtała PhD Maciej Gagat PhD Adam Kowalewski MD Dariusz Grzanka MD, PhD
author_sort	Justyna Durślewicz MSc
title	Prognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Non–Small-Cell Lung Cancer Patients
title_short	Prognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Non–Small-Cell Lung Cancer Patients
title_full	Prognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Non–Small-Cell Lung Cancer Patients
title_fullStr	Prognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Non–Small-Cell Lung Cancer Patients
title_full_unstemmed	Prognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Non–Small-Cell Lung Cancer Patients
title_sort	prognostic significance of tlr2, smad3 and localization-dependent satb1 in stage i and ii non–small-cell lung cancer patients
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/0152040ae90b42beb633b0efa501df80
work_keys_str_mv	AT justynadurslewiczmsc prognosticsignificanceoftlr2smad3andlocalizationdependentsatb1instageiandiinonsmallcelllungcancerpatients AT annaklimaszewskawisniewskaphd prognosticsignificanceoftlr2smad3andlocalizationdependentsatb1instageiandiinonsmallcelllungcancerpatients AT jakubjozwickimdphd prognosticsignificanceoftlr2smad3andlocalizationdependentsatb1instageiandiinonsmallcelllungcancerpatients AT paulinaantosikphd prognosticsignificanceoftlr2smad3andlocalizationdependentsatb1instageiandiinonsmallcelllungcancerpatients AT martasmolinskaswitałaphd prognosticsignificanceoftlr2smad3andlocalizationdependentsatb1instageiandiinonsmallcelllungcancerpatients AT maciejgagatphd prognosticsignificanceoftlr2smad3andlocalizationdependentsatb1instageiandiinonsmallcelllungcancerpatients AT adamkowalewskimd prognosticsignificanceoftlr2smad3andlocalizationdependentsatb1instageiandiinonsmallcelllungcancerpatients AT dariuszgrzankamdphd prognosticsignificanceoftlr2smad3andlocalizationdependentsatb1instageiandiinonsmallcelllungcancerpatients
_version_	1718403962589151232

Prognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Non–Small-Cell Lung Cancer Patients

Ejemplares similares